SK Bioscience Begins Study of Sarbecovirus Vaccine
SK bioscience has initiated a global phase I/II clinical trial of GBP511, a universal vaccine candidate targeting the Sarbecovirus family, leveraging its SKYCovione recombinant protein platform and nanoparticle technology as part of the company’s mid- to long-term strategy to advance next-generation vaccines for future pandemic preparedness.
Comirnaty | 30/01/2026 | By News Bureau
Pfizer and BioNTech's Updated COVID-19 Vaccine Secures EMA Nod, Awaits Final EU Approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Pfizer- BioNTech's LP.8.1-adapted monovalent COVID-19 vaccine in the European Union.
COMIRNATY | 28/07/2025 | By Dineshwori | 216
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy